Cell therapies often rely on engineered receptors that are difficult to design, costly to produce, and can exhibit safety or efficacy limitations, restricting their use across oncology, autoimmunity, and fibrotic diseases.

Modularit provides a platform that creates interchangeable, modular receptor components for in vivo cell therapies. An AI‑driven protein design engine generates receptor variants optimized for binding specificity, signaling strength, and manufacturability. The modular architecture allows rapid swapping of ligand‑binding domains, signaling modules, and safety switches to tailor therapies for different disease targets. Produced receptors are engineered for stable expression in patient‑derived cells, reducing manufacturing complexity and enabling scalable, cost‑effective treatment pipelines. The platform integrates with existing cell‑therapy workflows, delivering validated receptor libraries that accelerate preclinical development and de‑risk clinical translation.

AI‑based protein design pipeline that predicts high‑affinity binding and optimal signaling profiles

Fully modular receptor architecture separating targeting, signaling, and safety domains for rapid reconfiguration

Built‑in safety switches (e.g., inducible apoptosis, cytokine release control) to mitigate adverse events

Compatibility with viral and non‑viral delivery methods for in vivo cell engineering

Scalable production workflow that reduces reagent costs and accelerates GMP manufacturing

Comprehensive validation suite including in vitro potency assays and in vivo efficacy models

Primary customers are biotech firms and pharmaceutical R&D groups developing engineered cell therapies for cancer, autoimmune disorders, and fibrotic conditions.